French biopharmaceutical company Inventiva SA on Thursday revealed it has expanded its U.S. share sale to approximately $150 million, as the clinical-stage firm detailed its plans to use the capital to advance liver disease therapies and support general corporate operations. Originally, Inventiva announced Wednesday it intended to sell $125 million worth of new American depositary French Inventiva $150M Share Sale: Biopharma boosts Nasdaq offering to fund liver disease trials.
French biopharmaceutical company Inventiva SA on Thursday revealed it has expanded its U.S. share sale to approximately $150 million, as the clinical-stage firm detailed its plans to use the capital to advance liver disease therapies and support gene… [888 chars]
Source: USA Herald | Published: 2025-11-13T18:52:31Z
Credit: USA Herald
